News

Thomas Geelhaar, Head of Chemicals R&D at Merck in Darmstadt, Germany, describes how the company scouts for technologies and interacts with universities.

The UK biotech sector has fallen victim to the mayhem in the capital markets. After a year of falling share prices, five quoted companies have put up “for sale” signs.